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Objective. This study evaluated the prevalence, awareness, and type of treatment for hypertension in Brazil in patients with type 1
diabetes (T1D).Methods. This was a cross-sectional, multicenter study that was conducted fromDecember 2008 to December 2010
in 28 public clinics located in 20 Brazilian cities. Results. A total of 3,591 patients were studied, 56% female, average age 21.2 ± 11.7
years, with a median duration of diabetes 9.6 ± 8.1 years. Blood pressure levels were available for a total of 3,323 patients and
689 (19.2%) patients were hypertensive. Hypertensive patients were older, exhibited longer duration of diabetes, and had higher
body mass index (BMI), total cholesterol, triglycerides, and LDL-C values (𝑃 < 0.001, for all comparisons), but only 370 (53.7%)
received treatment. Patient awareness of hypertension was documented in 453 (65.5%) patients. However, only 76 (22.9%) of the
treated patients attained the target systolic (sBP) and diastolic blood pressures (dBP). Conclusions. Our results demonstrate that a
large number of T1D patients with hypertension do not receive appropriate treatment; few of the treated T1D patients achieved the
target sBP and dBP values. Greater attention should be paid to blood pressure evaluation, hypertension diagnosis, and treatment
of T1D patients in Brazil.
1. Introduction
Type 1 diabetesmellitus (T1D) is a chronic disease that carries
a great risk of morbidity and mortality, as a result of the
microvascular and macrovascular complications that reduce
an affected individual’s quality of life and life expectancy
[1]. Progress in diabetes management in recent decades has
improved the survival rates amongT1Dpatients, although life
expectancy remains lower for these individuals compared to
nondiabetic subjects of equal age [2].
Diabetes has emerged as a major health problem in
societies in which noncommunicable diseases are the most
common causes of disability and death [1, 2]. Furthermore,
diabetes treatment has become a large financial burden
because of the increased associated direct and indirect costs
[3].
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Theoccurrence of hypertension inT1Dpatients is directly
correlated with the presence of microvascular complications,
primarily nephropathy and retinopathy and the progres-
sion of these chronic complications [4, 5]. There is strong
evidence, relating to the efficacy and cost effectiveness of
treatment, to support blood pressure control in T1D and T2D
patients, as well as the nondiabetic population, for reducing
levels ofmorbidity andmortality [6–8]. Target blood pressure
levels have been described in many guidelines, including
the American Diabetes Association (ADA) [9], American
Heart Association (AHA) [10], and BrazilianDiabetes Society
(BDS) [11]. However, a large gap remains between the rec-
ommendations for blood pressure control and the values that
have been described in most observational T1D [12–14] and
T2D [15] studies.
Previous studies on the prevalence, awareness, treatment
type, and control of hypertension have examined nondiabetic
populations or T2D patients [16, 17] but rarely T1D patients.
The Coronary Artery Calcification in type 1 Diabetes Study
(CACT1) [12] demonstrated a higher rate of hypertension
among T1D (43%) patients compared to nondiabetic subjects
(15%) but observed a similar rate of hypertension awareness
between T1D subjects (53%) and controls (45%). Further-
more, the EURODIAB study demonstrated a hypertension
prevalence of 24% among T1D patients and less than half of
these patients were aware of this condition. Only 42.2% of
the T1D patients in this study received treatment, and only
26.7% of the treated T1D patients attained the established
blood pressure targets [13].
The results of these studies emphasize the difficulties
associated with the treatment of hypertensive T1D patients
in routine clinical care and the need for improved treatment
quality.
The absence of national data on the prevalence, aware-
ness, type of treatment, and control of hypertension in T1D
patients led the Brazilian Type 1 Diabetes Study Group
(BrazDiab1SG) to conduct this study, seeking to provide
current and reliable data on the topic with regard to the ADA
guidelines.
2. Research Design and Methods
This was a multicenter, cross-sectional, and observational
study that was conducted between December 2008 and
December 2010 in 28 public secondary (ambulatory outpa-
tient clinics) and tertiary care level clinics (ambulatory out-
patient clinics in university hospitals), located in 20 cities in
four Brazilian geographic regions (north/northeast, midwest,
southeast and south). The detailed data collection methods
have been described previously [18]. Briefly, all patients
received health care from the National Brazilian Health Care
System (NBHCS). All eligible participating centers possessed
a diabetes clinic with at least one endocrinologist. Each
clinic provided data from a minimum of 50 consecutive
outpatients with an initial diagnosis of T1D who regularly
attended the clinic. The inclusion criteria consisted of a
diagnosis of T1D by a physician that was based on the typical
clinical presentation, including variable degrees of weight
loss, polyuria, polydipsia, and polyphagia, and the need for
continuous insulin use since T1D diagnosis. All patients were
diagnosed between 1960 and 2010.
The following variables were assessed in each interview
during the clinical visit: current age, age at diagnosis, duration
of diabetes (y), height (m), weight (kg), mean blood pressure
(systolic and diastolic in mmHg from three consecutive
measurements in one day using a standard clinical sphygmo-
manometer), modality of diabetic treatment, comorbidities,
frequency of SBGM, and smoking status. The levels of
glycated hemoglobin (HbA1c), fasting plasma glucose (FPG),
total cholesterol, LDL cholesterol, HDL cholesterol, and
triglycerides on the last clinical visit were obtained from
medical records. The screenings for retinopathy, using fun-
doscopy; nephropathy, according to microalbuminuria; and
foot examinations in patients with diabetes duration equal
or greater than five years were noted when these procedures
were performed within one year of the study assessment.
Demographic, educational, and economic data were also
obtained. Patients with diabetes for less than five years were
not included in the analysis of diabetic chronicmicrovascular
complications (𝑛 = 1, 160, 32.3%). Each local center’s
ethics committee approved the study (the appendix). The
Brazilian Diabetes Society (BDS) monitored and reviewed all
study-related documents and approved all amendments and
publications. Each center’s coordinator reviewed the chart
form prior to final approval.
The following ADA goals for adequate metabolic and
clinical control [11] were adopted by the BrazDiab1SG: HbA1c
< 7.5% for T1Dpatients of 13 to 19 years of age,HbA1c< 8% for
T1D patients of six to twelve years of age, HbA1c > 7.5% and <
8.5% for T1D for patients less than 6 years of age, and HbA1c
< 7% for adult T1D patients; systolic blood pressure (sBP)
< 130mmHg; diastolic blood pressure (dBP) < 80mmHg;
body mass index (BMI) < 25 kg/m2; FPG < 130mg/dL
(7.2mmol/L); total cholesterol < 200mg/dL (5.2mmol/L);
HDL cholesterol > 40mg/dL for men (1.1mmol/L) and
> 50mg/dL (1.3mmol/L) for women; LDL cholesterol <
100mg/dL (2.6mmol/L); non-HDL cholesterol < 130mg/dL
(3.30mmol/L); and triglycerides < 150mg/dL (1.7mmol/L).
Hypertension in adults was defined as sBP ≥ 140mmHg
and/or dBP ≥ 90mmHg, measured during the last clinical
visit [8] or was self-reported, while hypertension in children
and adolescentswas defined as a sBPor dBP≥ 95th percentile,
according to the patient’s age, sex,missimg and height [19]
with themeasurements taken during the clinical visit. Patient
awareness of hypertension in adults was based on patient self-
reporting of any prior hypertension diagnosis that was made
by a health practitioner on at least two separate occasions.
Patients who received angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs) for the
treatment of micro- or macroalbuminuria and those who
were not hypertensive were not included in the hypertensive
group (𝑛 = 197, 7.5%).
Microalbuminuria and clinical nephropathywere defined
according to the ADA recommendations [9]. Overweight
adults were defined as those with a BMI ≥ 25 kg/m2, and
obesity was defined as a BMI ≥ 30 kg/m2 [9]. Overweight
children and adolescents were defined as those with a BMI
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≥ the 85th percentile, and obesity was defined as a BMI ≥ the
95th percentile, according to the patient’s age and gender [20].
HbA1c values obtained in the last clinical visit and the cor-
responding measurement methods were collected from the
patients’ medical charts. HbA1cmeasurements were obtained
for 3,099 patients (86.2%), using methods that were certified
by the National Glycohemoglobin Standardization Program
(NGSP); of these, 1,766 patients (51.3%) were evaluated
using high-performance liquid chromatography, whereas
1,601 patients (46.6%) were evaluated using turbidimetry.
Measurements of HbA1c obtained using methods that were
not certified by the NGSP, missing data, and HbA1c measure-
ments obtained more than one year before the study assess-
ment were excluded from the glycemic control analyses (𝑛 =
494, 13.8%). FPG, triglycerides, HDL, and total cholesterol
were measured using enzymatic techniques. LDL levels were
calculated using Friedewald’s equation [21]. BMI (kg/m2) was
determined by dividing an individual’s weight (kg) by the
square of his\her height (m2). Current smoking was defined
as smoking more than one cigarette per day at the time of
the interview. Patients younger than 13 years of age were con-
sidered children (toddlers, preschoolers, or grade-schoolers),
patients ≥ 13 years and ≤ 18 years were deemed adolescents,
and patients > 18 years were considered adults [9].
2.1. Statistical Analysis. A detailed description of the study
sample calculation has been given previously [18]. Briefly,
the study sample represented the distribution of T1D cases
across four geographic regions in Brazil. The proportion
of cases from each region was estimated using the over-
all population distribution reported in the 2000 Brazilian
Institute of Geography and Statistics Population Census
(IBGE); 38.8%, 31.7%, 23.0%, and 6.6% of the population
was distributed in the southeast, north/northeast, south, and
midwest regions, respectively [22].These data were combined
with the national estimates of the prevalence of diabetes,
which were derived from a 1988 survey, to determine the
minimum number of patients to be studied in each region
[23]. Recruitment in each region of the country enrolled >
95% of the estimated number of T1D patients for the region.
Economic status was defined according to the Brazilian
Economic Classification Criteria [24]. This classification also
takes into account education level, which is categorized as
illiterate/incomplete primary education, complete primary
education/incomplete secondary education, complete sec-
ondary education/incomplete high school, complete high
school/some college, or complete college education. The
following classes of economic status were considered for this
analysis: high, middle, low, and very low [24].
Data are presented as the means (± SD) for continuous
variables and as counts (relative frequencies) for discrete
variables. For analyzing blood pressure data, the mean from
three consecutive measurements in a single day was used.
Comparisons between numeric variables were performed
using independent two-sided t-tests and two-sided z-tests
for discrete variables with a normal approximation to the
binomial distribution. An unadjusted Pearson’s correlation
coefficient was calculated when indicated. A multiple logistic
Table 1: Demographic data of the studied population.
Variable
Age, years 21.2 ± 11.7
Gender, female (%) 2,010 (56.0)
Age at diagnosis, years 10.0 (<1 to 44)
Age at diagnosis, years (%)
0–4.9 667 (18.5)
5–9.9 961 (26.8)
10–14.9 941 (26.2)
≥15 1,022 (28.5)
Diabetes duration, years 9.6 ± 8.1
Diabetes duration, years (%)
0–4.9 672 (18.7)
5–9.9 961 (26.8)
10–14.9 941 (26.2)
≥15 1,017 (28.3)
Level of care, 𝑛 (%)
Secondary 995 (27.7)
Tertiary 2,596 (72.3)
Geographic region (%)
Southeast 1,424 (39.7)
North/northeast 1,113 (31)
South 820 (22.8)
Mid-west 234 (6.5)
The data are presented as counts (percentage), means ± SD, or medians
(minimum/maximum). ∗African-Brazilians, Mulattos, Asians, and Native
Indians; ∗∗Data were available for 3,434 patients.
regression (Forward-Wald) was performed with hyperten-
sion (yes/no) as the dependent variable. The following inde-
pendent variables were included: race (Caucasian or non-
Caucasian based on self-reporting), age, BMI, geographic
region, gender, urine albumin excretion rate, and economic
status. The Nagelkerke 𝑅 square value was also calculated for
this analysis. All of the analyses were performed using SPSS
version 16.0 (Statistical Package of Social Sciences, Chicago,
IL, USA). Odds ratios with 95% confidence intervals (CI)
were performed when indicated. A two-sided 𝑃 value less
than 0.05 was considered significant.
3. Results
The clinical and demographic data for the study population
are shown in Table 1. The majority of the patients evaluated
were less than 30 years old (𝑛 = 1, 077, 30%).
Due to missing data, in the total population of 3,591
patients, 268 (7.5%) could not be classified as either hyperten-
sive or normotensive. Among the 3,323 (92.5%) T1D patients
evaluated, a total of 689 (19.2%) of the studied patients were
considered hypertensive, 236 (6.6%) were based on actual
blood pressure measurements, and 453 (12.6%) were based
on a history of or treatment for hypertension (self-reported).
Hypertension was more frequent in adults than in children
or adolescents (𝑛 = 562 (31.3%) versus 𝑛 = 127 (8.3%),
respectively,𝑃 < 0.001). Patients with hypertension were also
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Table 2: Demographic, clinical, and laboratory data for the presence of hypertension in the studied population.
Variables Hypertension
∗
Yes (%) No (%)
𝑃 value
𝑛 (%) 689 (19.2) 2,634 (73.4) —
Age, years 30.5 ± 12.8 19.7 ± 10.4 <0.001
Age at diagnosis of diabetes, years 14.8 ± 9.1 11.2 ± 7.6 0.19
Gender, female 𝑛 (%) 318 (21.9) 1,136 (78.1) 0.19
Duration of diabetes, years 15.7 ± 9.6 8.5 ± 7.0 <0.001
Race, 𝑛 (%) <0.001
Caucasian 353 (18.2) 1,585 (81.8)
Non-Caucasian 336 (24.3) 1,049 (75.7)
Economic status, 𝑛 (%)∗∗ 0.02
High 62 (26.6) 171 (73.4)
Medium 174 (23.2) 575 (76.8)
Low 208 (18.9) 890 (81.1)
Very low 242 (21.3) 896 (78.6)
BMI (Kg/m2) 24.0 ± 4.7 21.4 ± 3.9 <0.001
Overweight/obesity, 𝑛 (%) 276 (40.5) 767 (29.5) <0.001
Fasting glycemia (mg/dL) 179.7 ± 107.1 182.5 ± 105.7 0.5
HbA1c (%) 9.3 ± 2.4 9.3 ± 2.3 0.8
HbA1c < 7%, 𝑛 (%) 77 (12.8) 294 (13.0) 0.7
sBP (mmHg) 128.4 ± 20.7 107.9 ± 12.7 <0.001
dBP (mmHg) 81.31 ± 3.3 69.5 ± 9.4 <0.001
Total cholesterol (mg/dL) 178.5 ± 48.0 168.7 ± 39.6 <0.001
Triglycerides (mg/dL) 110.5 ± 85.4 89.0 ± 63.6 <0.001
HDL cholesterol (mg/dL) 53.4 ± 16.9 52.5 ± 14.0 <0.001
LDL cholesterol (mg/dL) 104.3 ± 39.7 99.0 ± 31.5 0.001
Current smoker, y (%) 31 (4.5) 110 (4.2) 0.9
Insulin dose (U/Kg/day) 0.83 ± 0.36 0.93 ± 0.39 <0.001
Number of clinical visits (previous year) 4.07 ± 1.7 4.10 ± 1.6 0.6
∗Missing cases 268 (7.5%).
∗∗Missing cases 130 (3.6%).
BMI: body mass index; sBP: systolic blood pressure; dBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Overweight/obesity were considered together.
The data are presented as counts (percentage) or means ± SD; ∗African-Brazilians, Mulattos, Asians, and Native Indians.
older, exhibited longer duration of diabetes and had higher
BMI, total cholesterol, triglycerides, LDL-C, and HDL-C
values than patients without hypertension (𝑃 < 0.001 for all
comparisons). These data are listed in Table 1.
A greater number of children and adolescents had miss-
ing blood pressure data than did adults (258 (96.3%) versus 10
(3.7%), respectively, 𝑃 < 0.001), and these data are indicated
in Table 2.
The mean age at the time of hypertension diagnosis
was 20 ± 10.3 years, and the self-reported duration of
hypertension was 3 years (range < 1 to 44 years). Patients who
were aware of their hypertension were older (𝑃 < 0.001) and
exhibited higher sBP (𝑃 = 0.001) and fewer borderline sBP of
140mmHg (𝑃 = 0.01) and borderline dBP of 90mmHg (𝑃 =
0.02) compared to patients who were unaware. A total of 370
(53.7%) of the hypertensive patients received treatment.More
patients aware of their hypertensive status received treatment
than did patients who were unaware of their condition (𝑃 <
0.001). These data are presented in Table 3.
Higher SBP and dBP values were also observed in treated
patients compared to untreated patients (sBP: 132.99 ± 19.4
versus 123.1 ± 21.2mmHg, respectively, 𝑃 < 0.001, and dBP:
83.00 ± 12.32 versus 79.12 ± 14.20mmHg, respectively, 𝑃 <
0.001). In total, 207 (55.9%) of the 370 treated patients were
administered only one antihypertensive agent; of these, 161
(43.5%) patients used ACE inhibitors and 46 (12.4%) patients
received monotherapy with calcium channel blockers (𝑛 = 5,
1.3%), beta blockers (𝑛 = 10, 2.7%), angiotensin receptor
blockers (ARBs) (𝑛 = 15, 4.1%), or diuretics (𝑛 = 16,
4.3%). A total of 122 (33%) patients received two drugs in
the following combinations: ACE inhibitors plus diuretics,
ARBs, beta blockers or calcium channel blockers, and ARBs
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Table 3: Hypertension awareness.
Variables Hypertension awareness
Yes (%) No (%)
𝑃 value
𝑛 (%) 453 (65.7) 236 (34.3) —
Children and adolescents,
𝑛 (%) 28 (22) 99 (78) <0.001
∗
Adults, 𝑛 (%) 425 (75.6) 137 (24.4)
sBP (mmHg) 129.8 ± 20.1 124.1 ± 21.9 0.001
dBP (mmHg) 81.5 ± 12.4 80.1 ± 15.2 0.1
Borderline sBP (140mmHg)
(%) 11 17.4 0.01
Borderline dBP (90mmHg)
(%) 17 28.4 0.01
Antihypertensive treatment
(%) 67.3 11.8 <0.001
∗
𝑃 < 0.001 (children and adolescents versus adults).
sBP: systolic blood pressure; dBP: diastolic blood pressure.
The data are presented as counts (percentage) or means ± SD.
plus diuretics or calcium channel blockers. Forty-one (11.1%)
patients received triple therapy with ACE inhibitors and
diuretics plus ARBs, beta blockers or calcium channel block-
ers.
A total of 76 (22.9%) treated hypertensive patients
achieved the targeted blood pressure range.The patients’ sBP
values correlated with age (𝑟 = 0.47, 𝑃 = 0.001), diabetes
duration (𝑟 = 0.41, 𝑃 < 0.001), total insulin dose (𝑟 = −0.17,
𝑃 < 0.001), AER (𝑟 = 0.16, 𝑃 < 0.001), BMI (𝑟 = 0.44, 𝑃 <
0.001), total cholesterol (𝑟 = 0.11, 𝑃 = 0.001), triglycerides
(𝑟 = 0.10, 𝑃 = 0.001), HDL cholesterol (𝑟 = 0.05, 𝑃 = 0.01)
and LDL cholesterol (𝑟 = 0.07, 𝑃 = 0.001). The dBP values
correlated with age (𝑟 = 0.40, 𝑃 = 0.001), diabetes duration
(𝑟 = 0.32, 𝑃 < 0.001), total insulin dose (𝑟 = −0.12, 𝑃 <
0.001), AER (𝑟 = 0.16,𝑃 < 0.001), BMI (𝑟 = 0.38,𝑃 < 0.001),
total cholesterol (𝑟 = 0.15, 𝑃 = 0.001), triglycerides (𝑟 = 0.14,
𝑃 < 0.001), HDL cholesterol (𝑟 = 0.05, 𝑃 = 0.01), and LDL
cholesterol (𝑟 = 0.07, 𝑃 = 0.001).
Patients with proliferative retinopathy or nonproliferative
retinopathy had higher sBP and dBP values than patients
without retinopathy (sBP: 124.5 ± 20.6 versus 121.2 ± 19.2
versus 113.1 ± 15.6mmHg, respectively, 𝑃 < 0.001, and dBP:
78.5 ± 11.9 versus 76.9 ± 11.5 versus 72.5 ± 10.8mmHg,
respectively, 𝑃 < 0.001). Additionally, patients with clinical
nephropathy or microalbuminuria had higher sBP and dBP
values than patients without nephropathy (sBP: 123.3 ± 21.1
versus 120.9 ± 17.9 versus 113.3 ± 15.8mmHg, respectively,
𝑃 < 0.001, and dBP: 78.7 ± 12.6 versus 76.6 ± 10.7 versus
72.5 ± 10.7mmHg, respectively, 𝑃 < 0.001).
Multivariate logistic analysis revealed that hypertension
was directly associated with age (OR = 1.06; 95% CI (1.05–
1.076; 𝑃 < 0.001)), BMI (OR = 1.13; 95% CI (OR = 1.09–
1.17; 𝑃 < 0.001)), AER level [OR = 1.02; 95% CI (1.01–1.03;
𝑃 < 0.001)] and male gender [OR = 1.35; 95% CI (1.02–1.80;
𝑃 < 0.001)]. Caucasian race was also associated with a lower
odds ratio of hypertension (OR = 0.68; 95% CI (0.51–0.91;
𝑃 = 0.01)). This model described 25.3% of the probability
of hypertension for a given patient.
4. Discussion
This study demonstrated that, while nearly 20% of the
patients examined exhibited hypertension, only 53.7% of
these patients received treatment. Moreover, only 22.3% of
the treated hypertensive patients achieved the targeted sBP
and dBP values. Hypertension was more common in non-
Caucasian adults and was associated with microvascular
complications and other cardiovascular risk factors, such as
being overweight or obese and exhibiting dyslipidemia.
The ADA provides recommended blood pressure levels
for all diabetic patients, but approximately 7.5%of the patients
participating in the current study received no such evaluation
in the year prior to the study. This was commonly observed
primarily in children and adolescents, as well as individuals
from the north/northeast and midwest regions of Brazil.
Some diabetes clinical care centers in Brazil may not include
blood pressure evaluations in their routine care of children
and adolescents. Although hypertension was more frequent
among adults (31.3%), in our diabetic study population, 8.3%
of diabetic children and adolescents also were hypertensive.
Few studies of hypertension in T1D patients have been
conducted; the majority of these studies analyzed hyperten-
sion in adult diabetic patients and reported a prevalence
of 24 to 43% [12–14, 25–29], which is similar to those
observed in the current study. In addition, an observational
study in Rio de Janeiro, Brazil, identified a hypertension
prevalence of 6.8% in nondiabetic children and adolescents
[30]. Our data on children and adolescents are similar to
those published by the Search Study (5.9%) [26], although
our prevalence figures were higher than those published
(4%) in a recent Norwegian study [29]. Studies of elevated
sBP or dBP in children and adolescents (greater than the
90th percentile for age, gender, and height) have reported a
prevalence of hypertension between 6% and 23%, depending
on the presence of other cardiovascular risk factors [26–
29]. Additionally, the prevalence of hypertension has been
shown to increase fourfold in overweight or obese children
and adolescents [29]. Age, diabetes duration, the presence
of chronic complications, race, and the number of medical
visits with available blood pressure evaluations may account
for the differences between our study and those conducted
previously.
More than one-third of our patients who were unaware of
their hypertensive condition were children and adolescents.
Importantly, all of these patients were treated by an endocri-
nologist in secondary and tertiary care settings.
Diabetes treatment in public clinics is financed by the
NBHCS, and our data reveal that factors other than medical
recommendations might likely interfere with diabetes care in
Brazil [18, 31].
The guidelines recommend aggressive hypertension
treatment in T1D patients, but only 53.7% of our patients
received such treatment; similar results were described in the
EURODIAB study [13]. In the current study, the majority of
treated patients (55.9%) received only one antihypertensive
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drug, whereas 44.1% received two or more drugs. These
results are in contrast with the results of previous studies
reporting that up to 19% of T1D patients received two
antihypertensive agents [12, 13]. In addition, only 11.1% of the
patients in the current study received triple therapy, which
is higher than the percentage described in the CACT1 (7%)
and EURODIAB (1.9%) studies.The abovementioned studies
were conducted 5 to 10 years before our study, suggesting that
an increase in the intensity of hypertension treatment has
occurred in recent years, as previously observed in a temporal
analysis of EURODIAB [32]. However, less than one-third of
our patients and T1D patients in the EURODIAB study [13]
exhibited controlled sBP and dBP levels, which suggests that
factors beyond pharmacological treatment might influence
blood pressure control. Additionally, compared to our
study, a larger percentage of the CACT1 patients (up to
64%) exhibited controlled blood pressure levels [12]. This
difference may be attributed to study design, as the patients
in the EURODIAB and our corresponding studies were not
volunteers.
The Pittsburgh Epidemiology of Diabetes Complica-
tions Study utilized different targets for blood pressure and
demonstrated small improvements in hypertension control,
primarily in younger-aged groups of T1D patients, over a 10-
year follow-up period [33]. One study that was performed at
academic medical centers observed a low rate of medication
management when T1D patients remained above their blood
pressure goal [34]. As factors such as hypertension, obesity,
and being overweight are indicators of CVD risk, we con-
cluded that the young patients that were evaluated represent
a high-risk group for the development of microvascular and
macrovascular complications associated with diabetes, as
described previously [4, 5, 26–28]. Furthermore, our study
demonstrated a clear association between the different stages
of retinopathy and nephropathy and increasing levels of
blood pressure.
The BrazDiab1SG is the only national registry on the
prevalence, awareness, and treatment of hypertension in T1D;
the principal strength of our study is our large sample size,
which included a representative sample of T1D distribution
in the young Brazilian population. Importantly, our study
included patients from a wide range of racial backgrounds
from all geographic regions of the country, and it maintained
a uniform, standard recruitment protocol at all of the partic-
ipating centers.
However, several limitations of the current study must
be addressed. We used a clinical definition of T1D that was
assigned by physicians and was applicable to all patients,
which is similar to previous studies [15, 16]. However, autoan-
tibody and C-peptide levels were not measured. Therefore,
some patients with other types of diabetes may have been
included. Nevertheless, it is important to emphasize that
93.1% of our patients were diagnosed before the age of 30,
which supports the high probability that these patients had
T1D. Also, as all of the patients in this study lived in large
cities and were seen in a public center by a specialist, patients
who relied on primary care facilities and lived in rural areas
may have been overlooked. Although 14% of the Brazilian
population lives in rural areas, the prevalence of T1D in this
group is very low [34], and consequently rural T1D patients
represent the minority of patients who receive treatment in
Brazil. Additionally, patients recruitment within each center
may have produced a selection bias for age because the
majority of our patients were younger than 30 years of age.
Moreover, there were missing data for blood pressure mea-
surements, which were primarily observed in the youngest
patients. Additionally, the prevalence of hypertension may
have been overestimated because diagnosis was based on the
measurement of a blood pressure in one day rather than two
separate measurements on two separate days. Although we
used a standard clinical sphygmomanometer, the possibility
formisclassification remains, especially, at borderline diagno-
sis levels for sBP and dBP. Misclassification was noted in our
sample in the analysis of the lack of hypertension awareness,
which was more frequent in the borderline group of patients.
The use of self-reported hypertension as a criterion for
awareness may have also produced a bias in the diagnosis of
this condition.
Therefore, to our knowledge, this research constitutes the
first national report on the prevalence of hypertension in
T1D in Brazil, a disease with increasing incidence in our
country [35].Our results demonstrate thatmanyT1Dpatients
with hypertension do not receive antihypertensive treatment;
moreover, few treatedT1Dpatients receive combined therapy,
and few of these patients achieve their targeted sBP and
dBP values. The evaluation of blood pressure in children
and adolescents is likely not included in all routine diabetic
clinical care centers. Thus, greater attention should be paid
to blood pressure evaluation and hypertension diagnosis and
treatment for T1D patients in Brazil.
Appendix
∗Brazilian Type 1 Diabetes Study Group
(BrazDiab1SG)
Executive Steering Committee: Marilia Brito Gomes (Chair),
Roberta Cobas, Sergio Atala Dib and Carlos Negrato. Univer-
sidade Estado Rio de Janeiro: Roberta Cobas∗, Alessandra
Matheus, Lucianne Tannus; Universidade Federal Rio de
Janeiro: Lenita Zajdenverg∗,Melanie Rodacki; Hospital Geral
de Bonsucesso: Neuza Braga Campos de Arau´jo∗, Marilena
de Menezes Cordeiro; Hospital Universita´rio Clementino
Fraga Filho—IPPMG: Dr. Jorge Luiz Luescher∗; Renata
Szundy Berardo; Servic¸o de Diabetes da Disciplina de
Endocrinologia e Metabologia do Hospital das Cl´ınicas da
Universidade de Sa˜o Paulo: Marcia Nery∗; Catarina Cani;
Maria do Carmo ArrudaMarques; Unidade de Endocrinolo-
gia Pedia´trica da Santa Casa de Miserico´rdia de Sa˜o Paulo:
Luiz Eduardo Calliari∗, Renata Maria de Noronha; Instituto
da Crianc¸a do Hospital das Cl´ınicas da Universidade de Sa˜o
Paulo: Thais Della Manna∗, Roberta Salvodelli, Fernanda
Garcia Penha; Hospital das Cl´ınicas da Faculdade de Medic-
ina de Ribeira˜o Preto—USP: Milton Cesar Foss∗, Maria
Cristina Foss-Freitas; Ambulato´rio da Faculdade Estadual
de Medicina de Sa˜o Jose´ do Rio Preto: Antonio Carlos
Pires∗, Fernando Cesar Robles; Associac¸a˜o de Diabe´ticos de
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Bauru: Carlos Antonio Negrato∗, Maria de Fatima Guedes;
Centro de Diabetes da Escola Paulista de Medicina: Ser-
gio Atala Dib∗, Patricia Dualib; Cl´ınica de Endocrinologia
da Santa Casa de Belo Horizonte Setor Diabetes Tipo 1:
Saulo Cavalcanti da Silva∗, Janice Sepulveda; Ambulato´rio
Multiprofissional de Atendimento a` Diabetes do Hospital
de Cl´ınicas da Universidade Estadual de Londrina: Hen-
riqueta Guidio de Almeida∗, Emerson Sampaio; Hospital
de Cl´ınicas da Universidade Federal do Parana´: Rosangela
Roginski Rea∗, Ana Cristina Ravazzani de Almeida Faria;
Instituto da Crianc¸a com Diabete Rio Grande Sul: Bal-
duino Tschiedel∗, Suzana Lavigne, Gustavo Adolfo Cardozo;
Hospital de Cl´ınicas de Porto Alegre: Mirela Azevedo∗,
Luis Henrique Canani, Alessandra Teixeira Zucatti; Hospital
Universita´rio de Santa Catarina:MarisaHelena Cesar Coral∗,
Daniela Aline Pereira; Instituto de Diabetes-Endocrinologia
de Joinville: Luiz Antonio de Araujo∗; Hospital Regional de
Taguatinga, Bras´ılia: Hermelinda Cordeiro Pedrosa∗, Monica
Tolentino; Flaviene Alves Prado; Hospital Geral de Goiaˆnia:
Dr Alberto Rassi: Nelson Rassi∗, Leticia Bretones de Araujo;
Centro de Diabetes e Endocrinologia do Estado da Bahia:
Reine Marie Chaves Fonseca∗; Alexis Dourado Guedes,
Odelisa Silva de Mattos; Universidade Federal do Maranha˜o:
Manuel Faria∗, Rossana Azulay; Centro Integrado de Dia-
betes e Hipertensa˜o do Ceara´: Adriana Costa e Forti∗, Maria
Cristina Fac¸anha; Universidade Federal do Ceara´: Renan
Montenegro Junior∗, Ana Paula Montenegro; Universidade
Federal de Sergipe: Naira HortaMelo∗, Karla Freire Rezende;
Hospital Universita´rio Alcides Carneiro: Alberto Ramos∗;
Hospital Universita´rio Joa˜o de Barros Barreto, Para´: Joa˜o
Soares Felicio∗, Flavia Marques Santos; Hospital Univer-
sita´rio Getu´lio Vargas, Hospital Adriano Jorge: Deborah
Laredo Jezini∗.
Abbreviations
ADA: American Diabetes Association
CV: Cardiovascular
T1D: Type 1 diabetes
BDS: Brazilian Diabetes Society
sBP: Systolic blood pressure
dBP: Diastolic blood pressure
BMI: Body mass index
HbA1C: Glycated hemoglobin
T2D: Type 2 diabetes
FBG: Fasting blood glucose
NBHCS: National Brazilian Health Care
System
BrazDiab1SG: Brazilian Type 1 Diabetes Study
Group,
SBGM: Self-blood glucose monitoring
HDL: High-density lipoprotein
LDL: Low-density lipoprotein
NGSP: National Glycohemoglobin
Standardization Program
ACE: Angiotensin-converting enzyme
ARBs: Angiotensin receptor blockers
AER: Albumin excretion rate.
Consent
Written informed consent for the study was obtained from all
patients or their parents when necessary.
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